Arcturus Therapeutics Holdings (ARCT) Operating Leases (2019 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 8 years of Operating Leases data on file, last reported at $19.7 million in Q1 2026.

• Quarterly Operating Leases fell 17.96% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (down 17.96% YoY) and the FY2025 annual result came in at $20.8 million, down 16.86% from the prior year.
• Operating Leases retreated to $19.7 million in Q1 2026, from $20.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $32.2 million in Q2 2022 to a low of $4.1 million in Q1 2022.
• A 5-year average of $24.9 million and a median of $26.0 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases declined 28.95% — and 2023, when it soared 619.42%.
• Tracing ARCT's Operating Leases over 5 years: stood at $30.2 million in 2022, then fell by 14.26% to $25.9 million in 2023, then slipped by 3.51% to $25.0 million in 2024, then decreased by 16.86% to $20.8 million in 2025, then retreated by 5.31% to $19.7 million in 2026.
• The last three Operating Leases figures came in at $19.7 million (Q1 2026), $20.8 million (Q4 2025), and $21.9 million (Q3 2025), per Business Quant data.